Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Laura Denouden

Internal Medicine Boone, NC Medical Doctor

NPI 1003929985 CMS profile 272531

614 Howard St, Boone, NC 28608

Open in the dashboard

General payments

$4,778

350 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Laura Denouden of Boone, NC is reported in the CMS Open Payments database as having received $4,778 across 350 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $435 28
2021 General $1,448 102
2020 General $1,309 97
2019 General $1,587 123

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Laura Denouden
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Laura Denouden were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Laura Denouden Internal Medicine median Middle half National median
2019 $1,587 $159 $48–$570 $163
2020 $1,309 $119 $33–$402 $114
2021 $1,448 $135 $37–$521 $132
2022 $435 $141 $42–$496 $149
2023 $0 $149 $45–$519 $160
2024 $0 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. Boehringer Ingelheim Pharmaceuticals, Inc. $813 59 payments
  2. Lilly USA, LLC $462 35 payments
  3. AstraZeneca Pharmaceuticals LP $459 25 payments
  4. Pfizer Inc. $445 33 payments
  5. Allergan Inc. $358 39 payments
  6. Biohaven Pharmaceuticals, Inc. $325 29 payments
  7. Amgen Inc. $272 19 payments
  8. Janssen Pharmaceuticals, Inc $202 17 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $197 11 payments
  10. GlaxoSmithKline, LLC. $163 11 payments
  11. Other $1,083 72 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Food and Beverage $4,778 350 payments
Products named General payments · program years 2019–2022
  1. SPIRIVA RESPIMAT $472 32 payments
  2. JARDIANCE Diabetes $460 35 payments
  3. TRULICITY $341 27 payments
  4. JARDIANCE Diabetes $330 26 payments
  5. NURTEC ODT $325 29 payments
  6. FARXIGA $299 16 payments
  7. TRINTELLIX $185 10 payments
  8. BEVESPI AEROSPHERE $181 6 payments
  9. ELIQUIS $181 13 payments
  10. XARELTO $177 15 payments
  11. Other $3,900 288 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

350 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record